JUAN IGNACIO ARENAS MIRAVE-rekin lankidetzan egindako argitalpenak (9)

2012

  1. Accurate fat fraction quantification by multiecho gradient-recalled-echo magnetic resonance at 1.5 T in rats with nonalcoholic fatty liver disease

    European Journal of Radiology, Vol. 81, Núm. 6, pp. 1122-1127

  2. Effect of neoadjuvant chemotherapy in hepatic steatosis

    Chemotherapy, Vol. 58, Núm. 2, pp. 89-94

  3. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

    Cancer Cell International, Vol. 12

2010

  1. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method

    World Journal of Gastroenterology, Vol. 16, Núm. 12, pp. 1495-1499

  2. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  3. Inflammatory mediators of hepatic steatosis

    Mediators of Inflammation, Vol. 2010

  4. Niveles plasmóticos de la vitamina B12 y ácido fólicoenpacientes con hepatopatía crónica

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 4, pp. 280-287

2008

  1. Resveratrol inhibits nonalcoholic fatty liver disease in rats

    BMC Gastroenterology, Vol. 8

2006

  1. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice

    BMC Gastroenterology, Vol. 6